- Home
- NXE vs MIRM Comparison
NXE vs MIRM Comparison
Compare NXE & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NXE | MIRM |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 5.7B |
| IPO Year | 2017 | 2019 |
Fundamental Metrics
Financial Performance| Metric | NXE | MIRM |
|---|---|---|
| Price | $10.28 | $93.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $119.85 |
| AVG Volume (30 Days) | ★ 6.1M | 899.6K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 74.59 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $19,138,000.00 |
| Revenue This Year | N/A | $26.22 |
| Revenue Next Year | $75.07 | $22.04 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.26 | $45.37 |
| 52 Week High | $13.96 | $114.99 |
Technical Indicators
Market Signals| Indicator | NXE | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 39.05 | 42.38 |
| Support Level | $7.79 | $87.26 |
| Resistance Level | $13.26 | $98.03 |
| Average True Range (ATR) | 0.55 | 4.55 |
| MACD | -0.01 | -1.14 |
| Stochastic Oscillator | 0.00 | 22.14 |
Price Performance
Historical ComparisonAbout NXE Nexgen Energy Ltd.
NexGen Energy Ltd is an exploration and development stage entity engaged in the acquisition, exploration, evaluation, and development of uranium properties in Canada. The Rook I Project is a development-stage uranium project in Canada. The Company also holds a prospective portfolio of uranium exploration projects in the historic eastern Athabasca Basin.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.